Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.36 |
| ▸ | NCF1 | P14598 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.33 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23978561 | 0.85 | CYP1A2 (0.46) | CYP1A2PCSK9TLR8RPS6KB1NCF1 | |
| SCHEMBL26488447 | 0.81 | CYP1A2 (0.43) | CYP1A2PCSK9TLR8RPS6KB1NCF1 | |
| SCHEMBL12003727 | 0.77 | CYP1A2 (0.56) | CYP1A2NCF1HTR3AHRH4KDM4E | |
| SCHEMBL31391395 | 0.77 | CYP1A2 (0.56) | CYP1A2NCF1HTR3AHRH4KDM4E | |
| SCHEMBL23978672 | 0.77 | CYP1A2 (0.45) | CYP1A2PCSK9TLR8RPS6KB1NCF1 | |
| SCHEMBL27947605 | 0.74 | CYP1A2 (0.51) | CYP1A2TLR8 | |
| SCHEMBL3337226 | 0.73 | CYP1A2 (0.47) | CYP1A2NCF1HTR3AHRH4KDM4E | |
| SCHEMBL17061539 | 0.73 | CYP1A2 (0.47) | CYP1A2NCF1HTR3AHRH4KDM4E | |
| SCHEMBL14505627 | 0.70 | CYP1A2 (0.42) | CYP1A2PCSK9TLR8NCF1HTR3A | |
| Hydrochloric Acid SCHEMBL10583130 | 0.69 | CYP1A2 (0.47) | CYP1A2NCF1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135152-A1 | PIKFYVE KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-04 | — | — | US | disclosed |
| WO-2021163727-A1 | PIKFYVE KINASE INHIBITORS | AcuraStem Incorporated (US) | 2021-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135152-A1 | PIKFYVE KINASE INHIBITORS | PIKFYVE, PIP5K1B, PIP5K1C | CYP1A2 4578/4885PCSK9 2241/4885ACACB 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.